Proteomics International has been granted a new patent that has important longer-term potential value to our company.
Whilst further research is required to confirm the viability of our biomarker as a drug target, any pharmaceutical company in the USA seeking to develop a treatment using this novel target will need to reach commercial agreement with Proteomics International.
